相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide
Taymeyah Al-Toubah et al.
ONCOLOGIST (2021)
Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors
Sandrine Oziel-Taieb et al.
ANTICANCER RESEARCH (2021)
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET
Murali Kesavan et al.
ENDOCRINE-RELATED CANCER (2021)
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Satya Das et al.
CURRENT ONCOLOGY REPORTS (2021)
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
H. Jeong et al.
ESMO OPEN (2021)
177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience
Swayamjeet Satapathy et al.
JCO GLOBAL ONCOLOGY (2021)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Louis de Mestier et al.
NEUROENDOCRINOLOGY (2020)
The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms
Hao Xie et al.
NEUROENDOCRINOLOGY (2020)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
George Papaxoinis et al.
NEUROENDOCRINOLOGY (2020)
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
Taymeyah Al-Toubah et al.
ONCOLOGIST (2020)
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors
James R. Howe et al.
PANCREAS (2020)
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
Katharine Thomas et al.
CANCERS (2020)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y
M. Pavel et al.
ANNALS OF ONCOLOGY (2020)
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multicenter analysis of treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3).
Leonidas Apostolidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis
Dwight H. Owen et al.
Journal of the National Comprehensive Cancer Network (2020)
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Malcolm H. Squires et al.
PANCREAS (2020)
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
Jin Won Kim et al.
CANCER RESEARCH AND TREATMENT (2020)
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
David Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses
Louis de Mestier et al.
NEUROENDOCRINOLOGY (2019)
Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE).
Paul Girot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
Eleftherios Chatzellis et al.
NEUROENDOCRINOLOGY (2019)
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis
Wojciech Rogowski et al.
ENDOKRYNOLOGIA POLSKA (2019)
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma
Katharine E. H. Thomas et al.
ONCOLOGIST (2019)
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases
Jordan M. Cloyd et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond
Halfdan Sorbye et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
Aman Chauhan et al.
JOURNAL OF ONCOLOGY (2018)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Pamela L. Kunz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).
Manali A. Bhave et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Guido Rindi et al.
MODERN PATHOLOGY (2018)
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study
Davide Campana et al.
ENDOCRINE (2018)
Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases
Arvind Dasari et al.
CANCER (2018)
Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors
Laura Prakash et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2017)
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T. Walter et al.
EUROPEAN JOURNAL OF CANCER (2017)
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience
Guillermo Crespo et al.
FUTURE ONCOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology Well Differentiated Versus Poorly Differentiated
Nitya Raj et al.
PANCREAS (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
1132OEVEROLIMUS (EVE) FOR THE TREATMENT OF ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET): FINAL OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, MULTICENTER PHASE III TRIAL (RADIANT-3)
J.C. Yao et al.
ANNALS OF ONCOLOGY (2017)
Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors
Daniela Mueller et al.
BMC CANCER (2016)
DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications
Iris H. Liu et al.
CANCER TREATMENT REVIEWS (2016)
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
M. Cives et al.
ENDOCRINE-RELATED CANCER (2016)
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
J. Cros et al.
ENDOCRINE-RELATED CANCER (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
Romain Coriat et al.
ONCOLOGIST (2016)
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials
Pamela L. Kunz et al.
PANCREAS (2016)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
Tomohiro Yamaguchi et al.
CANCER SCIENCE (2014)
Outcomes of patients treated with capecitabine and temozolamide (CapTem) for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs
Renata D'Alpino Peixoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
Jennifer A. Chan et al.
CANCER (2013)
Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
Phillip G. Claringbold et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Phillip G. Claringbold et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chemotherapy and signaling How can targeted therapies supercharge cytotoxic agents?
Tetyana Bagnyukova et al.
CANCER BIOLOGY & THERAPY (2010)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC-FFCD 9710
Laetitia Dahan et al.
ENDOCRINE-RELATED CANCER (2009)
Clinical Implications of Microsatellite Instability and MLH1 Gene Inactivation in Sporadic Insulinomas
Mei Mei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeted modulation of MGMT: Clinical implications
LL Liu et al.
CLINICAL CANCER RESEARCH (2006)
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
WJ Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms
MG House et al.
ANNALS OF SURGERY (2003)
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282
RK Ramanathan et al.
ANNALS OF ONCOLOGY (2001)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
